Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Discriminatory plasma biomarkers predict specific clinical phenotypes of necrotizing soft-tissue infections

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Muscle-derived interleukin 6 increases exercise capacity by signaling in osteoblasts

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of immunoglobulin G on cytokine response in necrotising soft-tissue infection: a post-hoc analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hand hygiene compliance of healthcare workers before and during the COVID-19 pandemic: A long-term follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Adjunctive hyperbaric oxygen treatment for necrotising soft-tissue infections: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  • Laura M Palma Medina
  • Eivind Rath
  • Sanjeevan Jahagirdar
  • Trond Bruun
  • Martin B Madsen
  • Kristoffer Strålin
  • Christian Unge
  • Marco Bo Hansen
  • Per Arnell
  • Michael Nekludov
  • Ole Hyldegaard
  • Magda Lourda
  • Vitor Ap Martins Dos Santos
  • Edoardo Saccenti
  • Steinar Skrede
  • Mattias Svensson
  • Anna Norrby-Teglund
View graph of relations

BACKGROUNDNecrotizing soft-tissue infections (NSTIs) are rapidly progressing infections frequently complicated by septic shock and associated with high mortality. Early diagnosis is critical for patient outcome, but challenging due to vague initial symptoms. Here, we identified predictive biomarkers for NSTI clinical phenotypes and outcomes using a prospective multicenter NSTI patient cohort.METHODSLuminex multiplex assays were used to assess 36 soluble factors in plasma from NSTI patients with positive microbiological cultures (n = 251 and n = 60 in the discovery and validation cohorts, respectively). Control groups for comparative analyses included surgical controls (n = 20), non-NSTI controls (i.e., suspected NSTI with no necrosis detected upon exploratory surgery, n = 20), and sepsis patients (n = 24).RESULTSThrombomodulin was identified as a unique biomarker for detection of NSTI (AUC, 0.95). A distinct profile discriminating mono- (type II) versus polymicrobial (type I) NSTI types was identified based on differential expression of IL-2, IL-10, IL-22, CXCL10, Fas-ligand, and MMP9 (AUC >0.7). While each NSTI type displayed a distinct array of biomarkers predicting septic shock, granulocyte CSF (G-CSF), S100A8, and IL-6 were shared by both types (AUC >0.78). Finally, differential connectivity analysis revealed distinctive networks associated with specific clinical phenotypes.CONCLUSIONSThis study identifies predictive biomarkers for NSTI clinical phenotypes of potential value for diagnostic, prognostic, and therapeutic approaches in NSTIs.TRIAL REGISTRATIONClinicalTrials.gov NCT01790698.FUNDINGCenter for Innovative Medicine (CIMED); Region Stockholm; Swedish Research Council; European Union; Vinnova; Innovation Fund Denmark; Research Council of Norway; Netherlands Organisation for Health Research and Development; DLR Federal Ministry of Education and Research; and Swedish Children's Cancer Foundation.

Original languageEnglish
Article numbere149523
JournalThe Journal of clinical investigation
Volume131
Issue number14
ISSN0021-9738
DOIs
Publication statusPublished - 15 Jul 2021

ID: 66792485